CLevel Interviews Confirm Allogene (ALLO) Best Positioned Among Next Gen Cell Therapies - Piper Jaffray

Piper Jaffray analyst Tyler Van Buren reiterated an Overweight rating and $50.00 price target on Allogene (NASDAQ: ALLO) after conducting nearly 30 hours' worth of interviews with C-level management at numerous companies, including Allogene.

The analyst stated "While the first generation of cell therapy products has resulted in durable cures for some patients, there is much room for improvement and more importantly, there are significant limitations inherent to
the autologous process that simply cannot be overcome. Therefore, a core focus for the field is to transition to allogeneic therapy and we believe Allogene is best positioned. Indeed, management is leveraging their industry-leading expertise to develop allogeneic CAR-T products that exhibit highly-efficient and scalable manufacturing and enable pharmaceutical-like stocking".

For an analyst ratings summary and ratings history on Allogene click here. For more ratings news on Allogene click here.

Shares of Allogene closed at $29.85 yesterday.

You May Also Be Interested In

• Allogene Therapeutics, Inc. (ALLO) Tops Q2 EPS by 4c
• New Street Research Upgrades Micron Technology (MU) to Buy
• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'